Adrenocortical Carcinoma Market Report 2025

This Adrenocortical Carcinoma market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The adrenocortical carcinoma market size has grown steadily in recent years. It will grow from $3.6 billion in 2024 to $3.77 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth during the historic period can be attributed to several factors, including the rising incidence of adrenocortical carcinoma, greater awareness of rare endocrine tumors, and increased government and research funding. Additionally, the growing presence of patient support and advocacy groups, along with the rising prevalence of rare cancers, contributed to this growth.

The adrenocortical carcinoma market size is expected to see steady growth in the next few years. It will grow to $4.47 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The growth during the forecast period can be attributed to several factors, including the greater use of combination therapies, the rising adoption of personalized medicine, the expansion of clinical trials, increased involvement in international research networks, and a boost in government and research funding. Key trends expected during this period include advancements in genomic sequencing and personalized medicine, innovations in targeted therapies, developments in immunotherapy, progress in liquid biopsy technology, and improvements in biomarker identification.

The rising prevalence of rare cancers is expected to drive the growth of the adrenocortical carcinoma (ACC) market in the future. Rare cancers are characterized by their low incidence rates and their significant impact on patient outcomes, requiring specialized techniques for diagnosis and treatment. The increase in rare cancer cases can be attributed to various factors, including advancements in diagnostic methods that have improved the detection of adrenocortical carcinoma, enabling earlier identification of cases that might have previously gone undiagnosed. Adrenocortical carcinoma, a relatively uncommon yet aggressive form of cancer, contributes to the growing prevalence of rare cancers, emphasizing the need for better diagnosis and treatment approaches. For example, a report from the International Agency for Research on Cancer, part of the World Health Organization, noted in February 2022 that nearly six new cases of rare cancers are diagnosed annually per 100,000 individuals in the US. As a result, the increase in the prevalence of rare cancers is expected to fuel the expansion of the adrenocortical carcinoma market.

Key players in the adrenocortical carcinoma (ACC) market are focusing on the development of innovative therapies, such as small-molecule drugs, to target specific tumor pathways and enhance patient outcomes. Small-molecule drugs are low molecular weight compounds that enter cells to target proteins or enzymes, thereby regulating biological processes and treating diseases such as adrenocortical carcinoma by inhibiting tumor growth pathways. For example, in January 2023, Orphagen Pharmaceuticals, Inc., a pharmaceutical company based in the United States, announced that the U.S. Food and Drug Administration (FDA) had granted Rare Pediatric Disease Designation (RPDD) for its investigational drug OR-449, which is being developed to treat pediatric adrenocortical carcinoma (ACC). This drug specifically targets pediatric ACC, a rare and aggressive cancer that primarily affects children. The disease often manifests with symptoms related to hormonal overproduction, such as virilization and Cushing syndrome. Diagnosis is typically carried out through imaging and hormonal assessments, with prognosis influenced by factors such as the age of diagnosis and the resectability of the tumor.

In October 2024, Esteve Pharmaceuticals, S.A., a pharmaceutical company based in Spain, acquired HRA Pharma Rare Diseases from Perrigo Company plc for an undisclosed amount. Through this acquisition, Esteve Pharmaceuticals seeks to broaden its portfolio of treatments for rare diseases, accelerate its international expansion, improve patient care, and expand its market presence. HRA Pharma Rare Diseases, based in France, is a pharmaceutical company focused on treating rare diseases, including adrenocortical carcinoma.

Major players in the adrenocortical carcinoma market are Roche Holding AG, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Medtronic plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Ipsen S.A., Ferring Pharmaceuticals Inc., Exelixis Inc., Alnylam Pharmaceuticals Inc., Mylan N.V., HRA Pharma S.A., Servier Laboratories, Tempest Therapeutics Inc., Orphagen Pharmaceuticals Inc., and Millendo Therapeutics Inc.

North America was the largest region in the adrenocortical carcinoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in adrenocortical carcinoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the adrenocortical carcinoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Adrenocortical carcinoma (ACC) is a rare and aggressive form of cancer that begins in the outer layer (cortex) of the adrenal glands. The adrenal glands are small, triangular organs located on top of each kidney and are responsible for producing hormones that regulate metabolism, immune function, blood pressure, and stress response. ACC can disrupt hormone production, leading to symptoms such as weight gain, high blood pressure, and virilization (the development of male physical traits).

There are two main types of adrenocortical carcinoma, localized and metastatic. Localized adrenocortical carcinoma is a rare and aggressive cancer that remains confined to the adrenal gland, without spreading to other areas of the body. Treatment for these conditions involves various methods, including surgery, chemotherapy, targeted therapy, radiation therapy, and adjuvant therapy. The primary end users of these treatments are hospitals, clinics, ambulatory surgical centers, and cancer research institutions.

The adrenocortical carcinoma market research report is one of a series of new reports that provides adrenocortical carcinoma market statistics, including the adrenocortical carcinoma industry global market size, regional shares, competitors with the adrenocortical carcinoma market share, detailed adrenocortical carcinoma market segments, market trends, and opportunities, and any further data you may need to thrive in the adrenocortical carcinoma industry. This adrenocortical carcinoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The adrenocortical carcinoma market consists of revenues earned by entities by providing services such as diagnostic services, medical treatments, patient management services, clinical trials, and research. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.